Contraceptive update for GPs: PBS oral contraceptives, estetrol, drospirenone, and shorter pill-free intervals
Associate Professor Gina Pepperaro reviews why Australia leans so heavily on the pill, what is new or newly PBS-relevant, how combined hormonal contraception actually works, and how to frame thrombosis risk against pregnancy — with NuvaRing-type delivery and 24/4 packs in the mix.
- Associate Professor Gina Pepperaro — obstetrician-gynaecologist
- Obstetrician-gynaecologist in Brisbane; senior clinical lecturer in obstetrics and gynaecology, University of Queensland. Otter transcript spelling retained (“Pepperaro”); host introduction used “he’s” — we do not invent a corrected surname and refer to the speaker by name and specialty.
- HealthEd / Health Edge opener — Raylene
- On-demand learning team announcement (podcast CPD micro-activity and 2× playback) before the clinical talk.
GP-facing summary of one Gold Coast CPD seminar on Saturday 30 May 2026 (Otter title: “Contraceptive Update Seminar”; otter id cb2NEog0HMVzJhoj_2m0nZ8JOd8). About 26 minutes (~1558 s). It is not personal medical advice and not a substitute for product information, current PBS listings, or the patient in front of you.
Otter.ai garbles some drug and brand names (estetrol/E4, drospirenone, Yasmin/Yaz, NuvaRing, Seasonique, ethinylestradiol). Where the recording is unclear, this write-up cleans the clinical term rather than inventing doses, PBS item numbers, or guideline claims the speaker did not make.
Australia’s OCP habit and long consults
The talk was deliberately narrow: new and PBS-relevant oral contraceptives, because the PBS is still how most patients afford medication. That is not the same as “cheapest pregnancy protection.” If cost alone mattered after abstinence, the speaker pointed to long-acting methods — Mirena lasting about seven years, and some older copper IUDs lasting about fourteen years — where cost per year of contraception is often lower than daily pills.
Yet Australia is an outlier in WHO-framed contraceptive behaviour: we rely on oral contraceptives more than LARCs or other methods. The speaker’s suspicion is cultural comfort with tablets — familiarity, perceived safety, and trust — rather than a purely clinical reason. That matters when you open a contraceptive discussion.
For a new contraceptive patient the speaker usually allocates a good 45 minutes to an hour. People have often tried multiple methods, do not know what they want, and frequently want something beyond “not pregnant” — lighter, less painful periods, predictable cycles. Take a full medical, surgical, and family history. Remember: oral contraceptives do not protect against sexually transmitted infections.
Unwanted pregnancy in Australia still has a bimodal age pattern — more at younger and later ages. Do not forget the perimenopausal woman whose partner’s behaviour has changed and who suddenly needs contraception again — she may also need infection protection. Related coast reading: reproductive health and high-risk pregnancy.
What is new or newly PBS-relevant
Three product themes in the seminar:
- A different oestrogen — estetrol (E4)
- A progestogen already familiar to many GPs — drospirenone — now with Yasmin and Yaz on the PBS as discussed in the talk
- A different delivery system — NuvaRing / NuvaRing-type vaginal ring with etonogestrel (same progestogen family as in Implanon), framed as newly memorable contraception on the PBS
The speaker was involved in early Australian acceptability work when the ring first arrived; reception was better than expected. The hormone is familiar; the delivery system is the real difference.
How CHC really works
Older medical-school teaching: oestrogen (classically ~30 micrograms ethinylestradiol) stopped ovulation, and progestogen mainly mimicked a “natural” cycle. Current reproductive-endocrinology framing in the talk: the progestogen is the central ovulation block. It also thins the endometrium (less implantation-friendly) and thickens cervical mucus. Oestrogen potentiates the progestogen, helps block FSH, and mainly stabilises the endometrium so bleeding is tolerable.
The speaker used progestogen deliberately: synthetic compounds acting at progesterone receptors. Natural progesterone is what ovaries produce. Combined pills are not contraceptives “because they turn on sex drive” — they work by blocking ovulation and changing the genital tract environment.
Estetrol (E4) vs ethinylestradiol
Naturally occurring oestrogens include estradiol (dominant in reproductive life), estrone, and estriol. Estetrol (E4) is also natural — produced by the fetal liver. Most traditional combined pills use synthetic ethinylestradiol (various microgram strengths; higher doses being phased out).
| Feature (from the talk) | Ethinylestradiol | Estetrol (E4) |
|---|---|---|
| Metabolism | Heavy hepatic metabolism; active metabolites; enterohepatic recirculation; long-acting feel | Absorbed well; little hepatic metabolism; “cleaner” molecule |
| Drug interactions | Cytochrome P450 induction/interactions with other drugs | Little CYP interaction as framed |
| SHBG / androgens | Raises SHBG — part of anti-androgen / acne story; sometimes linked to low libido | Does not raise SHBG the same way |
| Blood pressure | Can stimulate angiotensin precursors → BP rise in some | Minimal liver/kidney precursor effect as described |
| Breast | Can stimulate glandular proliferation; pregnancy-like mastalgia in some | Described as not stimulating breast-cell proliferation like other oestrogens |
| Half-life | Long via recirculation | ~24–28 hours — still protective window, different mechanism |
Combined pills are among the more carefully chosen prescriptions. The speaker is not a fan of pharmacists or nurse practitioners routinely commencing combined contraception — argue for access without sacrificing safety. That is a professional opinion from the seminar, not a legal summary of current scope-of-practice rules.
Estetrol was also flagged as interesting for future menopause / HRT-type combinations (CNS effect on hot flushes, bone protection, cardiovascular-friendly framing in the talk) — “watch this space,” not a claim that such products were already licensed at the time of the seminar.
Progestogens, drospirenone, and the ring
Older debates ranked “generations” of progestogens: rising thrombotic signal and falling androgenicity as generations ascended. Practical Australian context from the talk:
- Levonorgestrel — still the most popular OCP progestogen here; effective, some androgenic effect
- Etonogestrel — in NuvaRing-type products and Implanon; mild androgenic effect
- Drospirenone — in Yaz / Yasmin / related brands now on PBS as discussed; little androgenic effect, sometimes described as anti-androgenic
Drospirenone itself is not brand-new; what changed for clinic affordability is PBS listing of familiar brands. Choose progestogen with the patient’s side-effect goals (acne, bloating, androgenic effects) — not only “newest.”
Thrombosis risk vs pregnancy
Every combined-pill conversation eventually hits thrombosis and pulmonary embolism — magazines and social media amplify it. The speaker’s betting-person framing: put your money on contraception over pregnancy. Pregnancy multiplies thrombosis risk by orders of magnitude compared with combined pills’ small absolute rise. The highest-risk window in a woman’s life for thrombosis is the six weeks after birth (third trimester/postpartum framing in the talk).
Statistical significance in epidemiology is not the same as clinical significance for the person opposite you. Individualise — that is what professionalism is for.
21/7 vs 24/4 pill-free interval
Classic Australian packets: 21 active + 7 sugar pills. The bleed is a withdrawal bleed, not a true period. UK packaging culture differs (21-day packs trusting women to count seven off days). The newer pattern emphasised in the talk: 24 active + 4 hormone-free days.
Modern women have far more periods than ancestors who spent more of life pregnant. Ask what bleeding profile she wants. Most can cope with a regular, predictable bleed; unpredictable spotting is what sinks morale. Continuous use of traditional packs often leads to breakthrough bleeding after about three months. A relatively new Seasonique-type seasonal continuous product takes the guesswork out of counting packets for a period each season — noted in the talk as not on the PBS.
Individualising the contraceptive consult
Take-homes the speaker wanted in the last minutes of a short talk:
- Treat contraception as a proper medical encounter — right method for this stage of life, knowing needs change
- Pills do not cover STIs; condoms still matter when both pregnancy and infection protection are needed
- If the driver is pure cost, discuss LARC cost-per-year honestly versus “I only want a pill”
- Ask what else they want: less breast tenderness/mastalgia, acne, heavy or irregular bleeding, PCOS/PMDD issues
- Ask about personal and family thrombophilia / thrombosis worry
- Ask about compliance — if they will not take a tablet every day, a long-acting method may fit better
- Cyclical symptoms and desire to skip periods change the pack pattern (traditional continuous vs Seasonique-type vs 24/4)
The speaker’s line: clinical significance and individualisation beat conference soundbites and rigid protocols. Know the science, listen actively, and decide with the patient.
Take-home messages
- Australia over-uses OCPs relative to LARCs; cost-per-year often favours IUDs/implants — still respect patient preference
- PBS-relevant updates discussed: estetrol (E4), drospirenone brands (Yasmin/Yaz), NuvaRing-type etonogestrel ring, and 24/4 packs
- Progestogen is the main ovulation block; oestrogen stabilises endometrium and supports the progestogen
- Frame VTE risk against pregnancy and postpartum peak; individualise
- Short pill-free intervals help bleeding volume and hormone-sensitive symptoms
- STI protection is separate; long consults and active listening are part of good care
drkotha.com · lilac theme · allcpd.drkotha.com/contraceptive-update/